SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001636282-23-000016
Filing Date
2023-11-09
Accepted
2023-11-09 16:06:30
Documents
14
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K agle-20231109.htm   iXBRL 8-K 32056
2 EX-99.1 agle-20230930xexx991.htm EX-99.1 107254
6 GRAPHIC a9.jpg GRAPHIC 3675
  Complete submission text file 0001636282-23-000016.txt   290879

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT agle-20231109.xsd EX-101.SCH 1908
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT agle-20231109_lab.xml EX-101.LAB 26177
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT agle-20231109_pre.xml EX-101.PRE 13592
8 EXTRACTED XBRL INSTANCE DOCUMENT agle-20231109_htm.xml XML 2931
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 231392340
SIC: 2834 Pharmaceutical Preparations